Boron Containing Doai Patents (Class 514/64)
-
Publication number: 20140259230Abstract: A method of controlling phytopathogenic diseases on useful plants or plant propagation material thereof, which comprises applying to said plant or plant propagation material a fungicidally effective amount of a compound of formula (I) wherein all the substituent save indicated as in claim 1.Type: ApplicationFiled: October 8, 2012Publication date: September 11, 2014Applicant: SYNGENTA PARTICIPATIONS AGInventors: Carla Bobbio, Christophe Weider, Ronald Zeun, Ramya Rajan, Daniel Stierli
-
Publication number: 20140242190Abstract: Methods for preventing and/or reducing side effects of an anti-cancer agent in a subject in need thereof are disclosed. The method comprises administering to the subject, who is under an anti-cancer agent treatment, a composition comprising a therapeutically effective amount of isolated deoxyelephantopin and/or an analogue thereof; and a pharmaceutically acceptable carrier.Type: ApplicationFiled: May 2, 2014Publication date: August 28, 2014Applicant: Academia SinicaInventors: Lie-Fen SHYUR, Wen-Wan CHAO, Ya-Wen CHENG
-
Publication number: 20140243286Abstract: Described herein are monomers capable of forming a biologically useful multimer when in contact with one, two, three or more other monomers in an aqueous media. In one aspect, such monomers may be capable of binding to another monomer in an aqueous media (e.g. in vivo) to form a multimer (e.g. a dimer). Contemplated monomers may include a ligand moiety, a linker element, and a connector element that joins the ligand moiety and the linker element. In an aqueous media, such contemplated monomers may join together via each linker element and may thus be capable of modulating one or more biomolecules substantially simultaneously, e.g., modulate two or more binding domains on a protein or on different proteins.Type: ApplicationFiled: February 28, 2014Publication date: August 28, 2014Applicant: Coferon, Inc.Inventors: Lee Daniel Arnold, Kenneth W. Foreman, Douglas S. Werner
-
Patent number: 8816095Abstract: Disclosed are molecules and their synthesis, for use in blocking gated ion channels such as voltage-gated sodium channels (VGSCs) and prostate voltage sodium channels (PVSCs). These inhibitors have superior blocking efficacy, for instance in displacing the radioligand [3H]-Batrachotoxin-B ([3H]-BTX-B) that binds to site 2 of a VGSC. The molecules of the invention comprise a moiety which increases the binding affinity of molecules for the protein binding site in prostate cancer cells (PCs), and which is also fluorescent. In one embodiment the invention molecules are an inhibition system that can be used to target over-abundant or hyperactive VGSCs selectively in pain, epilepsy or prostate cancer, inhibiting the proliferation of PCs. The fluorescent moiety also facilitates screening, tracking, and pharmacodynamic studies of the drug in a biological system both in vitro and in vivo.Type: GrantFiled: August 17, 2009Date of Patent: August 26, 2014Assignee: Georgetown UniversityInventors: Milton L. Brown, Scott Grindrod, Thomas H. Walls, Todd Hansen, Simeng Suy, Mikell A. Paige
-
Publication number: 20140234254Abstract: The present invention provides heteroaromatic derivatives and pharmaceutical acceptable salts and formulations thereof useful in modulating the protein kinase activity, especially phosphatidylinositol 3-kinases (PI3 kinases) and mTOR, and in modulating inter- and/or intra-cellular signaling activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.Type: ApplicationFiled: February 15, 2014Publication date: August 21, 2014Applicants: SUNSHINE LAKE PHARMA CO., LTD., CALITOR SCIENCES, LLCInventor: Ning Xi
-
Publication number: 20140235580Abstract: Provided herein are compounds which mediate the activity of monoacyglycerol lipase (MAGL). Also provided are pharmaceutical compositions comprising a compound provided herein, and methods for treating, preventing and/or managing a MAGL mediated condition using a compound or pharmaceutical composition as provided herein.Type: ApplicationFiled: September 27, 2012Publication date: August 21, 2014Inventors: Alfredo C. Castro, Stephane Peluso, Daniel A. Snyder, Thomas T. Tibbitts
-
Publication number: 20140235578Abstract: Various methods for treating a patient with neoplasia are disclosed, in particular, methods using topoisomerase Ila-preferential poisons, methods using a combination of a topoisomerase Illi-preferential inhibitor and a topoisomerase II poison, and methods using a combination of a topoisomerase II poison and a proteasome inhibitor are disclosed. Novel topoisomerase Ila-preferential poisons are disclosed, particularly, several novel 13-carboline derivatives are identified. Methods for identifying the novel topoisomerase Ila-preferential poisons and methods for identifying the novel topoisomerase EP-preferential inhibitors are also provided herein.Type: ApplicationFiled: March 24, 2014Publication date: August 21, 2014Applicant: Rutgers, The State University of New JerseyInventors: Leroy F. Liu, Yi L. Lyu, Anna M. Azarova, Johnson Y. Lau
-
Publication number: 20140235579Abstract: Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.Type: ApplicationFiled: April 28, 2014Publication date: August 21, 2014Inventors: John M. McCall, Donna L. Romero, Michael Clare
-
Patent number: 8809284Abstract: Contemplated compositions and methods are drawn to use of various boron-containing compounds to temporarily and transiently increase endogenous blood calcitriol concentration. The boron-containing compound is preferably a carbohydrate-boron complex having sufficient stability to achieve measurable quantities of the complex in blood upon oral administration of the complex.Type: GrantFiled: April 5, 2010Date of Patent: August 19, 2014Assignee: VDF Futureceuticals, Inc.Inventor: Zbigniew Pietrzkowski
-
Patent number: 8809282Abstract: The present invention relates, in general, to a method of treating patients undergoing enzyme replacement therapy (ERT) or other therapy involving the administration of a proteinaceous therapeutic agent as well gene replacement therapy with non-viral or viral vectors, or other therapeutic modality or modalities, used alone or in combination, which involve the administration of exogenous substances for potential therapeutic benefit, including, but not limited to DNA vaccines, siRNA, splice-site switching oligomers (SSOs) as well as RNA-based nanoparticles (RNPs) and nanovaccines. The invention further relates to compounds and compositions suitable for use in such methods.Type: GrantFiled: May 6, 2011Date of Patent: August 19, 2014Assignee: Duke UniversityInventors: Priya S. Kishnani, Suhrad G. Banugaria, Dwight D. Koeberl, Sean N. Prater
-
Publication number: 20140227201Abstract: Disclosed herein are formulations comprising an N-halogenated or N,N-dihalogenated amine compound dispersed in a water-swellable polymer, wherein the compound is 90% stable for at least 30 days at about 25° C. Also disclosed are methods of treating or preventing infections caused by a bacterial, a microbial, a sporal, a fungal or a viral activity using such formulations.Type: ApplicationFiled: February 13, 2013Publication date: August 14, 2014Inventors: Lu Wang, Azar Najafi, Bahram Memarzadeh, Kuldeepak Sharma, Kim Phuong Ho
-
Patent number: 8802240Abstract: Disclosed are methods of increasing the chemosensitivity of normal and/or chemoresistant tumor or cancer cells using thyroid hormone analogs and/or nanoparticulate or polymeric forms thereof. Also disclosed are methods of increasing radiosensitivity of normal and/or radioresistant tumor or cancer cells using thyroid hormone analogs and/or nanoparticulate or polymeric forms thereof.Type: GrantFiled: January 6, 2012Date of Patent: August 12, 2014Assignee: Nanopharmaceuticals LLCInventors: Paul J. Davis, Shaker A. Mousa
-
Publication number: 20140221313Abstract: The present invention is in the field of molecular diagnostics and relates to a method for classifying samples obtained from patients diagnosed with multiple myeloma into three newly defined clusters. The invention also relates to a method for determining the prognosis of an individual diagnosed with multiple myeloma as well as a method for the prediction of the response to treatment of an individual diagnosed with multiple myeloma. More in particular, the invention provides a method for determining the disease outcome or the prognosis of a patient diagnosed with multiple myeloma by classifying said patient into a high risk or a low risk category, based on a 92 gene classifier.Type: ApplicationFiled: July 12, 2012Publication date: August 7, 2014Applicant: Erasmus University Medical Center RotterdamInventors: Rowan Kuiper, Pieter Sonneveld
-
Publication number: 20140219989Abstract: The present invention provides a compound of Formula (I) as described herein, or a pharmaceutically acceptable salt thereof. The present invention also provides pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes.Type: ApplicationFiled: July 3, 2012Publication date: August 7, 2014Inventors: Craig Boyle, William Greenlee, Samuel Chackalamannil, Claire Lankin
-
Publication number: 20140221312Abstract: This invention is related to use of a volatile antimicrobial compound against pathogens affecting meats, plants, or plant parts. The volatile antimicrobial compounds provided include certain oxaborole compounds, for example benzoxaboroles. Delivery systems are provided to take advantage of the volatile nature of these antimicrobial compounds. Also combinations with a volatile plant growth regulator, for example 1-methylcyclopropene, are disclosed.Type: ApplicationFiled: January 29, 2014Publication date: August 7, 2014Applicant: DOW AGROSCIENCES LLCInventors: Daniel Maclean, David H. Young, Richard M. Jacobson, Maurice C. Yap, Rodrigo A. Cifuentes, Donald H. DeVries
-
Publication number: 20140212384Abstract: The present invention features a method for the treatment of Hepatitis C in a human in need thereof comprising administering a compound of Formulas (II) or (IIB) described herein or a pharmaceutically acceptable salt thereof in combination with one or more alternative Hepatitis C therapeutic agents.Type: ApplicationFiled: August 17, 2012Publication date: July 31, 2014Inventors: Jill Walker, Christian Voitenleitner
-
Publication number: 20140213552Abstract: The present application provides novel compounds and methods for preparing and using these compounds. These compounds are useful in treating pain, itch, overactive bladder and/or interstitial cystitis in patients by administering one or more of the compounds to a patient. The methods include administering a compound of formula (I) and a TRPV1 receptor activator. In one embodiment, the TRPV1 receptor activator is lidocaine.Type: ApplicationFiled: March 20, 2014Publication date: July 31, 2014Applicant: Endo Pharmaceuticals Inc.Inventors: Scott Kevin Thompson, Roger Astbury Smith, Sandeep Gupta, Tony Priestley, Nicholas James Laping, Ashis K. Saha, Sonali Rudra
-
Publication number: 20140213551Abstract: This invention is related to compounds and/or compositions useful against pathogens affecting meats, plants, or plant parts. In one embodiment, the provided compounds are products of certain oxaborole moieties. In a further embodiment, the compound comprises a di-oxaborole compound. Delivery systems are also provided to take advantage of the volatile nature of these compounds and/or compositions.Type: ApplicationFiled: February 18, 2014Publication date: July 31, 2014Applicant: Dow AgroScience LLCInventors: Richard Martin Jacobson, Daniel Maclean, Esther Gachango
-
Publication number: 20140206647Abstract: There is disclosed pyridine- and pyrimidinecarboxamide compounds useful as pharmaceutical agents, synthesis processes, and pharmaceutical compositions which include pyridine- and pyrimidinecarboxamides compounds. More specifically, there is disclosed a genus of CXCR2 inhibitor compounds that are useful for treating a variety of inflammatory and neoplastic disorders.Type: ApplicationFiled: March 26, 2014Publication date: July 24, 2014Applicant: SYNTRIX BIOSYSTEMS, INC.Inventors: Dean Y. Maeda, John A. Zebala
-
Publication number: 20140206648Abstract: Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to cyclic boronate compounds and their use as therapeutic agents.Type: ApplicationFiled: August 30, 2012Publication date: July 24, 2014Applicant: REMPEX PHARMACEUTICALS, INC.Inventors: Raja K. Reddy, Serge Henri Boyer, Maxim Totrov, Scott Hecker
-
Publication number: 20140206536Abstract: Disclosed are compounds of Formula 1, N-oxides, and salts thereof, wherein X is O or S; Y is O or S; A is O, S, NR3e or C(R3c)?C(R3d); Z is a direct bond, O, S(O)n, NR6, C(R7)2O, OC(R7)2, C(?X1), C(?X1)E, EC(?X1), C(?NOR8) or C(?NN(R6)2); a is 1, 2 or 3; and R1, R2, R3a-R3e, R4, R5, R6, R7, R8, X1 and E are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a compound or a composition of the invention.Type: ApplicationFiled: March 19, 2014Publication date: July 24, 2014Applicant: E I DU PONT DE NEMOURS AND COMPANYInventors: WENMING ZHANG, CALEB WILLIAM HOLYOKE, JR., KENNETH ANDREW HUGHES, GEORGE PHILIP LAHM, THOMAS FRANCIS PAHUTSKI, JR., MY-HANH THI TONG, MING XU
-
Patent number: 8785418Abstract: Lyophilized cakes of proteasome inhibitors are described, as well as methods for their production and use.Type: GrantFiled: September 29, 2011Date of Patent: July 22, 2014Assignee: Cephalon, Inc.Inventors: Denis Bricout, Helene Cambourieux, Michael L. Cappola, Nicole Frati, Piyush R. Patel
-
Publication number: 20140200198Abstract: Compounds, pharmaceutical formulations, and methods of treating anti-inflammatory conditions and/or helminth-associated diseases are disclosed.Type: ApplicationFiled: December 18, 2013Publication date: July 17, 2014Applicant: ANACOR PHARMACEUTICALS, INC.Inventors: Kurt Jarnagin, Tsutomu Akama
-
Publication number: 20140199291Abstract: The invention relates to compositions, methods, and kits for treating subjects infected by or at risk of infection with a DNA virus (e.g., a JC Virus or a BK virus). Aspects of the invention are useful to prevent or treat DNA virus associated conditions (e.g., PML) in subjects that are immunocompromised. Compositions are provided that inhibit intracellular replication of DNA viruses.Type: ApplicationFiled: September 13, 2008Publication date: July 17, 2014Applicant: Biogen Idec MA IncInventors: Leonid Gorelik, Margot Brickelmaier, Alexey Lugovskoy
-
Patent number: 8779149Abstract: There is disclosed aminopyridine- and aminopyrimidinecarboxamide compounds useful as pharmaceutical agents, synthesis processes, and pharmaceutical compositions which include aminopyridine- and aminopyrimidinecarboxamides compounds. More specifically, there is disclosed a genus of CXCR2 inhibitor compounds that are useful for treating a variety of inflammatory and neoplastic disorders.Type: GrantFiled: August 22, 2011Date of Patent: July 15, 2014Assignee: Syntrix Biosystems, Inc.Inventors: Dean Y. Maeda, John A. Zebala, Aaron D. Schuler
-
Publication number: 20140194385Abstract: Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents. Other embodiments relate to pharmaceutical compositions containing boronic acid derivatives and additional excipient such as meglumine.Type: ApplicationFiled: January 2, 2014Publication date: July 10, 2014Inventors: Raja K. Reddy, Tomasz Glinka, Maxim Totrov, Scott Hecker
-
Publication number: 20140194383Abstract: Described herein are monomers capable of forming a biologically useful multimer when in contact with one, two, three or more other monomers in an aqueous media. In one aspect, such monomers may be capable of binding to another monomer in an aqueous media (e.g. in vivo) to form a multimer, (e.g. a dimer). Contemplated monomers may include a ligand moiety, a linker element, and a connector element that joins the ligand moiety and the linker element. In an aqueous media, such contemplated monomers may join together via each linker element and may thus be capable of modulating one or more biomolecules substantially simultaneously, e.g., modulate two or more binding domains on a protein or on different proteins.Type: ApplicationFiled: April 9, 2012Publication date: July 10, 2014Applicants: Cornell University, Coferon, Inc., Purdue Research FoundationInventors: Francis Barany, Maneesh Pingle, Donald E. Bergstrom, Sarah F. Giardina, Lee Daniel Arnold
-
Publication number: 20140194384Abstract: Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents.Type: ApplicationFiled: January 2, 2014Publication date: July 10, 2014Inventors: Raja K. Reddy, Tomasz Glinka, Maxim Totrov, Scott Hecker
-
Publication number: 20140194386Abstract: Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.Type: ApplicationFiled: January 10, 2014Publication date: July 10, 2014Inventors: Christopher J. BURNS, Denis DAIGLE, Bin LIU, Daniel McGARRY, Daniel C. PEVEAR, Robert E. Lee TROUT, Randy W. JACKSON
-
Publication number: 20140194382Abstract: Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents.Type: ApplicationFiled: March 14, 2013Publication date: July 10, 2014Inventors: Raja Reddy, Tomasz Glinka, Maxim Totrov, Scott Hecker
-
Publication number: 20140194381Abstract: Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents.Type: ApplicationFiled: March 14, 2013Publication date: July 10, 2014Applicant: Rempex Pharmaceuticals, Inc.Inventor: Rempex Pharmaceuticals, Inc.
-
Publication number: 20140194387Abstract: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.Type: ApplicationFiled: January 13, 2014Publication date: July 10, 2014Applicant: Millennium Pharmaceuticals, Inc.Inventors: Paul E. Fleming, Jing Li
-
Patent number: 8772336Abstract: This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.Type: GrantFiled: October 11, 2012Date of Patent: July 8, 2014Assignees: Merck Frosst Canada Ltd., Axys Pharmaceuticals, Inc.Inventors: Christopher I. Bayly, Cameron Black, Serge Leger, Chun Sing Li, Dan McKay, Christophe Mellon, Jacques Yves Gauthier, Vouy-Linh Truong, Cheuk Lau, Michel Therien, Michael J. Green, Bernard L. Hirschbein, James William Janc, James T. Palmer, Chitra I. Baskaran
-
Publication number: 20140187510Abstract: The present invention is directed toward a method of treating a subject for a condition mediated by aberrant Wnt/?-catenin signaling by selecting a subject with a condition mediated by aberrant Wnt/?-catenin signaling and administering to the selected subject a compound selected from the group consisting of those set forth in Table 1, Table 2, and a pharmaceutically acceptable salt thereof. A method of similarly modulating the Wnt/?-catenin pathway in a subject is also discussed.Type: ApplicationFiled: July 11, 2013Publication date: July 3, 2014Applicants: THE GENERAL HOSPITAL CORPORATION, MASSACHUSETTS INSTITUTE OF TECHNOLOGY, UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR CENTER FOR COMMERCIALIZATIONInventors: Randall T. Moon, Travis L. Biechele, Nathan D. Camp, Stephen Haggarty, Daniel Fass
-
Patent number: 8765720Abstract: The present invention provides a method for treating multiple myeloma in a subject, comprising the step of administering to the subject a combination of COMPOUND 1 and bortezomib. The invention further provides a method for treating multiple myeloma in a subject, comprising the step of administering to the subject a combination of COMPOUND 1 and melphalan.Type: GrantFiled: November 9, 2011Date of Patent: July 1, 2014Assignee: Cephalon, Inc.Inventor: James R. Berenson
-
Publication number: 20140179631Abstract: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.Type: ApplicationFiled: February 25, 2014Publication date: June 26, 2014Applicant: Millennium Pharmaceuticals, Inc.Inventors: Paul E. Fleming, Jing Li
-
Publication number: 20140179618Abstract: The present invention provides an inhibitor of the ubiquitin-proteasome system for use in treating cancer in a patient, wherein the patient is assessed to establish that the cancer is associated with cells in which the functional activity of SMARCB1 is low or absent. In one embodiment, the patient has, or is suspected of having, breast cancer, an atypical teratoid rhabdoid tumour (AT/RT) and/or a malignant rhabdoid tumour (MRT). In one embodiment, the proteasome inhibitor is Bortezomib. Further aspects of the invention provide related uses and methods.Type: ApplicationFiled: November 21, 2012Publication date: June 26, 2014Inventor: Ulrike Nuber
-
Publication number: 20140171389Abstract: Administration of TH-302 or another hypoxia activated prodrug in combination with a pharmacological agent that down-regulates or inhibits homology directed repair (HDR) is useful for treating cancer.Type: ApplicationFiled: March 30, 2012Publication date: June 19, 2014Applicant: THRESHOLD PHARMACEUTICALS, INC.Inventor: Karen Curd
-
Publication number: 20140171390Abstract: Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.Type: ApplicationFiled: December 6, 2013Publication date: June 19, 2014Applicant: VenatoRx Pharmaceuticals, Inc.Inventors: Christopher J. BURNS, Denis DAIGLE, Bin LIU, Daniel McGARRY, Daniel C. PEVEAR, Robert E. Lee TROUT
-
Patent number: 8754121Abstract: Methods for treating melanoma in a subject in need thereof are disclosed. The method comprises administering to the subject a composition comprising a therapeutically effective amount of deoxyelephantopin or an analogue thereof; and a pharmaceutically acceptable carrier. Methods of inhibiting proliferation, migration and/or metastasis of melanoma cells in a subject in need thereof are also disclosed. Also disclosed are methods for reducing side effects of an anti-cancer agent in a subject in need thereof.Type: GrantFiled: August 19, 2011Date of Patent: June 17, 2014Assignee: Academia SinicaInventors: Lie-Fen Shyur, Wen-Wan Chao, Ya-Wen Cheng
-
Publication number: 20140162971Abstract: The present invention provides for compounds of formula (I) wherein A1, A2, A3, A4, X1, X2, Y1, L1, G1, Rx, and Ry have any of the values defined thereof in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).Type: ApplicationFiled: March 14, 2013Publication date: June 12, 2014Inventors: Le WANG, John K PRATT, Keith F. McDANIEL, Yujia DAI, Steven D FIDANZE, Lisa HASVOLD, John H. Holms, Warren M. KATI, Dachun LIU, Robert A Mantei, William J. McCLELLAN, George S. SHEPPARD, Carol K. Wada
-
Publication number: 20140162983Abstract: The present invention provides novel pyrimidine and pyridine compounds according to Formula (I), Formula (II), Formula (III), Formula (IV) and Formula (V) their manufacture and use for the treatment of hyperproliferative diseases including, but not limited to, cancer, lupus, allergic disorders, Sjogren's disease and rheumatoid arthritis. In preferred embodiments, the present invention describes irreversible kinase inhibitors including, but not limited to, inhibitors of Bruton's tyrosine kinase.Type: ApplicationFiled: June 10, 2012Publication date: June 12, 2014Applicant: Merck Patent GmbHInventors: Brian L. Hodous, Lesley Liu-Bujalski, Reinaldo Jones, Donald Bankston, Theresa L. Johnson, Igor Mochalkin, Ngan Nguyen, Hui Qiu, Andreas Goutopoulos, Nadia Brugger
-
Patent number: 8747908Abstract: The present invention provides wood preservative compositions comprising micronized particles. In one embodiment, the composition comprises dispersions of micronized metal or metal compounds. In another embodiment, the wood preservative composition comprises an inorganic component comprising a metal or metal compound and organic biocide. When the composition comprises an inorganic component and an organic biocide, the inorganic component or the organic biocide or both are present as micronized particles. When compositions of the present invention are used for preservation of wood, the micronized particles can be observed as uniformly distributed within the wood and there is minimal leaching of the metal and biocide from the wood.Type: GrantFiled: October 21, 2004Date of Patent: June 10, 2014Assignee: Osmose, Inc.Inventors: Robert M. Leach, Jun Zhang
-
Patent number: 8748623Abstract: There is disclosed pyridine-and pyrimidinecarboxamide compounds useful as pharmaceutical agents, synthesis processes, and pharmaceutical compositions which include pyridine-and pyrimidinecarboxamides compounds. More specifically, there is disclosed a genus of CXCR2 inhibitor compounds that are useful for treating a variety of inflammatory and neoplastic disorders.Type: GrantFiled: February 17, 2010Date of Patent: June 10, 2014Assignee: Syntrix Biosystems, Inc.Inventors: Dean Y. Maeda, John A. Zebala
-
Publication number: 20140148414Abstract: Prochelator compounds of Formula I or Formula II: are described, along with methods of using the same and pharmaceutical formulations or compositions containing the same.Type: ApplicationFiled: January 30, 2014Publication date: May 29, 2014Applicant: Duke UniversityInventors: Katherine J. Franz, Marina G. D. Leed
-
Publication number: 20140148398Abstract: Compounds useful for the treatment of giardiasis are described.Type: ApplicationFiled: October 12, 2011Publication date: May 29, 2014Applicants: The United States of America, as represented by the Secretary, Dept. of Health and Human Service, UNIVERSITY OF MARYLAND, COLLEGE PARKInventors: Wei Zheng, Catherine Chen, Juan Jose Marugan, Noel Southall, Christopher P. Austin, Andrey Galkin, Liudmila Kulakova, Osnat Herzberg
-
Publication number: 20140148413Abstract: The present embodiments relate to compositions and methods for treating the inflammatory response in a tissue or organ, such as the liver, by contacting the tissue with a tissue-specific gap junction inhibitor; and compositions and methods of reducing the toxicity of an agent by administering a gap junction inhibitor either simultaneously or sequentially with exposure to the agent. For example, inhibition of the liver-specific gap junction connexin 32 by 2 aminoethyoxydiphenyl-borate, effectively treats and/or prevents hepatotoxicity.Type: ApplicationFiled: June 22, 2011Publication date: May 29, 2014Applicants: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE GENERAL HOSPITAL CORPORATIONInventors: Suraj J. Patel, John M. Milwid, Martin L. Yarmush, Kevin R. King
-
Publication number: 20140142056Abstract: Disclosed herein are methods of treating, diagnosing, and prognosing GLUT-dependent cancers and OXPHOS-dependent cancers. In some embodiments, the methods comprise administering to a patient in need thereof a GLUT inhibitor and/or an OXPHOS inhibitor. The inhibitors may be administered before, concurrently, or after one another. Suitable GLUT-dependent cancers may include a GLUT4-dependent cancer, a GLUT8-dependent cancer, and a GLUT11-dependent cancer. Suitable GLUT inhibitors may include a GLUT4 inhibitor, a GLUT8 inhibitor, and a GLUT11 inhibitor. Suitable OXPHOS-dependent cancers may include mitochondrial OXPHOS-dependent cancers, including cancers that have developed resistance to treatment with a GLUT-inhibitor.Type: ApplicationFiled: November 6, 2013Publication date: May 22, 2014Applicant: NORTHWESTERN UNIVERSITYInventors: Malathy Shanmugam, Steven T. Rosen
-
Publication number: 20140142064Abstract: This invention relates to compounds useful for treating fungal infections, more specifically topical treatment of onychomycosis and/or cutaneous fungal infections. This invention is directed to compounds that are active against fungi and have properties that allow the compound, when placed in contact with a patient, to reach the particular part of the skin, nail, hair, claw or hoof infected by the fungus. In particular the present compounds have physiochemical properties that facilitate penetration of the nail plate.Type: ApplicationFiled: January 27, 2014Publication date: May 22, 2014Applicant: ANACOR PHARMACEUTICALS, INC.Inventors: Stephen J. Baker, Tsutomu Akama, Carolyn Bellinger-Kawahara, Vincent S. Hernandez, Karin M. Hold, James J. Leyden, Kirk R. Maples, Jacob J. Plattner, Virginia Sanders, Yong-Kang Zhang
-
Publication number: 20140135288Abstract: Provided herein are methods for selecting use of proteasome inhibitors.Type: ApplicationFiled: April 27, 2012Publication date: May 15, 2014Applicant: EMORY UNIVERSITYInventor: Leon Bernal-Mizrachi